FDA Approves Phase III Clinical Trial of Tocilizumab for COVID-19 Pneumonia
Hannah Slater
202014 citations
Abstract
The FDA has approved a phase III clinical trial to assess the safety and efficacy of intravenous tocilizumab (Actemra) plus standard of care in hospitalized adult patients with severe COVID-19 pneumonia.
Topics & Concepts
TocilizumabMedicineCoronavirus disease 2019 (COVID-19)PneumoniaClinical trialStandard of careSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakInternal medicinePhases of clinical researchIntensive care medicineVirologyOutbreakInfectious disease (medical specialty)DiseaseCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19Drug-Induced Hepatotoxicity and Protection